

Status: Currently Official on 17-Feb-2025  
 Official Date: Official Prior to 2013  
 Document Type: USP Monographs  
 DocId: GUID-66AE7F12-9DBF-4390-8E56-163F0792C53A\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M5365\\_01\\_01](https://doi.org/10.31003/USPNF_M5365_01_01)  
 DOI Ref: u8hl8

© 2025 USPC  
 Do not distribute

# Antipyrine, Benzocaine, and Phenylephrine Hydrochloride Otic Solution

» Antipyrine, Benzocaine, and Phenylephrine Hydrochloride Otic Solution is a solution of Antipyrine, Benzocaine, and Phenylephrine Hydrochloride in a suitable nonaqueous solvent. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amounts of antipyrine ( $C_{11}H_{12}N_2O$ ), benzocaine ( $C_9H_{11}NO_2$ ), and phenylephrine hydrochloride ( $C_9H_{13}NO_2 \cdot HCl$ ).

**Packaging and storage**—Preserve in tight, light-resistant containers.

**USP REFERENCE STANDARDS (11)**—

[USP Antipyrine RS](#)

[USP Benzocaine RS](#)

[USP Phenylephrine Hydrochloride RS](#)

**Identification**—The retention times of the major peaks in the chromatograms of the *Assay preparations* correspond to those in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

**Assay**—

*Mobile phase*—Mix 480 mL of acetonitrile, 3520 mL of a 0.005 M solution of sodium 1-heptanesulfonate in water, and 4 mL of phosphoric acid.

*Standard preparation*—Accurately weigh about 25 mg of [USP Antipyrine RS](#), about 25 mg of [USP Benzocaine RS](#), and about 25 mg of [USP Phenylephrine Hydrochloride RS](#) into a 250-mL volumetric flask. Add 5 mL of a 0.5 mg per mL solution of *p*-aminobenzoic acid in *Mobile phase*. Add 150 mL of *Mobile phase*, and mix to effect solution, sonicating if necessary. Dilute with *Mobile phase* to volume, and mix.

*Assay preparation A*—Transfer an accurately measured volume of Otic Solution, equivalent to about 100 mg of antipyrine, to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix. Pipet 5 mL of this solution into a 100-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Assay preparation B*—Transfer an accurately measured volume of Otic Solution, equivalent to about 100 mg of benzocaine, to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix. Pipet 5 mL of this solution into a 100-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Assay preparation P*—Transfer an accurately measured volume of Otic Solution, equivalent to about 5 mg of phenylephrine hydrochloride, to a 50-mL volumetric flask, dilute with *Mobile phase* to volume, and mix.

*Chromatographic system* (see [Chromatography \(621\)](#))—The liquid chromatograph is equipped with a 272-nm detector and a 4.6-mm × 30-cm column that contains packing L11. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.19 for *p*-aminobenzoic acid, 0.26 for phenylephrine, 0.64 for antipyrine, and 1.0 for benzocaine; the resolution, *R*, between phenylephrine and aminobenzoic acid is not less than 1.5, and the relative standard deviation for replicate injections is not more than 3.0%.

*Procedure*—Separately inject equal volumes (about 20 or 25 µL) of the *Standard preparation* and each of the *Assay preparations* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of antipyrine ( $C_{11}H_{12}N_2O$ ) in each mL of the Otic Solution taken by the formula:

$$(C/V)(r_U/r_S)$$

in which *C* is the concentration, in µg per mL, of [USP Antipyrine RS](#) in the *Standard preparation*; *V* is the volume, in mL, of Otic Solution taken; and *r<sub>U</sub>* and *r<sub>S</sub>* are the antipyrine peak responses obtained from *Assay preparation A* and the *Standard preparation*, respectively. Calculate the quantity, in mg, of benzocaine ( $C_9H_{11}NO_2$ ) in each mL of the Otic Solution taken by the formula:

$$(C/V)(r_U/r_S)$$

in which *C* is the concentration, in µg per mL, of [USP Benzocaine RS](#) in the *Standard preparation*; *V* is the volume, in mL, of Otic Solution taken; and *r<sub>U</sub>* and *r<sub>S</sub>* are the benzocaine peak responses obtained from *Assay preparation B* and the *Standard preparation*, respectively. Calculate the quantity, in µg of phenylephrine hydrochloride ( $C_9H_{13}NO_2 \cdot HCl$ ) in each mL of the Otic Solution taken by the formula:

$$50(C/V)(r_U/r_S)$$

in which *C* is the concentration, in µg per mL, of [USP Phenylephrine Hydrochloride RS](#) in the *Standard preparation*; *V* is the volume, in mL, of Otic Solution taken; and *r<sub>U</sub>* and *r<sub>S</sub>* are the phenylephrine peak responses obtained from *Assay preparation P* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ANTIPYRINE, BENZOCAINE, AND PHENYLEPHRINE HYDROCHLORIDE OTIC SOLUTION	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. Information currently unavailable

**Current DocID:** [GUID-66AE7F12-9DBF-4390-8E56-163F0792C53A\\_1\\_en-US](#)

**DOI:** [https://doi.org/10.31003/USPNF\\_M5365\\_01\\_01](https://doi.org/10.31003/USPNF_M5365_01_01)

**DOI ref:** [u8hl8](#)

OFFICIAL